To objectively evaluate the effectiveness of SPTLC2, AMD1, and IGSF3 in the diagnosis of AD, subsequent studies need to further verify the applied value of these findings through more experiments and clinical research. This evidence concerns the gene AMD1 and Alzheimer disease.